<DOC>
	<DOCNO>NCT02557867</DOCNO>
	<brief_summary>The purpose study study effect obesity dexmedetomidine pharmacokinetics pharmacodynamic profile .</brief_summary>
	<brief_title>The Effect Obesity Dexmedetomidine Metabolic Clearance</brief_title>
	<detailed_description>The investigator expect find inverse correlation amount fat mass liver blood flow enzymatic metabolic capacity . Results base population pharmacokinetic modeling analysis perform NONMEM program . The investigator first account effect different measure size scalar volume clearance search plausible covariates ( liver blood flow , enzymatic capacity , degree hepatic steatosis , etc ) dexmedetomidine metabolic clearance . A pharmacokinetic model capable characterize clearance change obese use plausible biological covariates try define .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Inclusion Criteria obese patient : American Society Anesthesiology classification IIII patient . Both gender . Age 18 60 year . Body mass index high 40 Kg/m2 . Inclusion Criteria nonobese patient : American Society Anesthesiology classification III patient Both gender . Age 18 60 year Body mass index lower 30 Kg/m2 . Known allergy study drug Uncontrolled hypertension . Heart block great first degree . Chronic hepatic kidney disease . Patients take drug act central nervous system within 24 hr surgery . Patients take drug induce overexpression liver cytochrome P450complex enzymes ( Carbamazepine , Phenytoin , Phenobarbital , Rifampicin , Dexamethasone , Griseofulvin , Terbinafine , Prednisone , Hydrocortisone , Modafinil ) . ) Known addiction illicit drug . Pregnancy . Current past oncologic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>dexmedetomidine</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>obesity</keyword>
</DOC>